Table 2 Clinical, immunological, and virological parameters of the study participants
Variables | No. (%) of study participant | |||
|---|---|---|---|---|
HIV positive | HIV negative n (%) | Total n (%) | ||
ART-naïve n (%) | On ART n (%) | |||
CD4+ T cell count (cells/µl) |  |  |  |  |
 Mean ± SD | 281 ± 127 | 442 ± 210 | 831 ± 106 | 518 ± 278 |
  < 200 | 29 (33.0%) | 20 (22.7%) | 0 (%) | 49 (18.6%) |
 200–500 | 48 (54.5%) | 31 (35.2%) | 0 (%) | 79 (29.9%) |
  > 500 | 11 (12.5%) | 37 (42.1%) | 88 (100%) | 136 (51.5%) |
HIV-1 viral load (copies/mL) | Â | Â | Â | Â |
 Median (IQR) | 191,837 (15,926–350,592) | 151 (75–8688) | – | 11,881 (151–201,874) |
  < 10,000 | 16 (18.2%) | 69 (78.4%) | – | 85 (48.3%) |
 10,000–100,000 | 21 (23.8%) | 17 (19.3%) | – | 38 (21.6%) |
  > 100,000 | 51 (58.0%) | 2 (2.3%) | – | 53 (30.1%) |
WHO clinical stage of HIV |  |  |  |  |
 Stage I | 44 (47.3%) | 93 (47.7%) | – | 137 (47.6% |
 Stage II | 28 (30.1%) | 62 (31.8%) | – | 90 (31.3%) |
 Stage III | 16 (17.2%) | 28 (14.4%) | – | 44 (15%) |
 Stage IV | 5 (5.4%) | 12 (6.2%) | – | 17 (5.9%) |
Duration of ART (years) | Â | Â | Â | Â |
 Mean ± SD | – | 3.2 ± 2.5 | – | 3.2 ± 2.5 |
  < 3 | – | 122 (62.6%) | – | 122 (62.6%) |
 ≥ 3 | – | 73 (37.4%) | – | 73 (37.4%) |